New diagnostic technologies, including molecular profiling, have enabled advances in treatments of various cancers; this hassignificantly improved clinical outcomes, including overall survival. However, thehigh cost of biologic drugs may prevent patients from having access to optimal treatment. Introduction of lower priced biosimilaragents into the therapeutic armamentarium brings the potential to ease the burden on healthcare expenditureand facilitate better access to effective cancer treatments. Oncology biosimilars have shown comparable efficacy and safety based on clinical evidence and physicochemical quality data as well as in real-world settings. This paper aims to reviewchanges in the management of oncology treatment and their implication with respect to biosimilars.
View details for DOI 10.2217/fon-2021-0546
View details for PubMedID 34189937